Heart failure & cardiomyopathies
Continuous Risk Monitoring and Management of Heart Failure: Rationale and Design of the ALLEVIATE-HF Trial
Study context
- Population
- NYHA class II or III heart failure (HF) with recent HF hospitalization, outpatient IV diuretics or elevated natriuretic peptides, without an implanted cardiac device or haemodynamic monitorplanned enrolment
- Participants
- ≈760 participants
- Planned comparison
- Insertable cardiac monitor (ICM)-guided intervention pathway vs observation
- Primary endpoint
- Hierarchical composite of CV death, HF events, KCCQ score and 6-min walk test distance
- Follow-up
- 13 months of randomized
Methodological detailsrationale and design, prospective, double-blind, multicentre, After 13 months of randomized follow-up, all patients enter an unblinded prolonged follow-up phase with PRN interventions upon high risk
- Rationale and design
- Prospective
- Double-blind
- Multicentre
- After 13 months of randomized follow-up, all patients enter an unblinded prolonged follow-up phase with PRN interventions upon high risk
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Continuous Risk Monitoring and Management of Heart Failure: Rationale and Design of the ALLEVIATE-HF Trial. Eur J Heart Fail. Published 27 January 2025. doi:10.
Summarised from the published abstract; every number is checked against it